Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Goldstein

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Journal of Medicinal Chemistry|April 10, 2014
Structure-based drug design of RN486, a potent and selective Bruton's tyrosine kinase (BTK) inhibitor, for the treatment of rheumatoid arthritisYan Lou, Xiaochun Han, Andreas Kuglstatter, et al.
Bioorganic & Medicinal Chemistry Letters|December 28, 2016
Mitigation of reactive metabolite formation for a series of 3-amino-2-pyridone inhibitors of Bruton's tyrosine kinase (BTK)Yan Lou, Francisco Lopez, Yongying Jiang, et al.
Journal of Medicinal Chemistry|February 14, 2014
Using ovality to predict nonmutagenic, orally efficacious pyridazine amides as cell specific spleen tyrosine kinase inhibitorsMatthew C Lucas, Niala Bhagirath, Eric Chiao, et al.
Journal of Medicinal Chemistry|August 11, 2012
Potent and highly selective benzimidazole inhibitors of PI3-kinase deltaJeremy M Murray, Zachary K Sweeney, Bryan K Chan, et al.
Journal of Medicinal Chemistry|March 18, 2022
Discovery of Reversible Covalent Bruton's Tyrosine Kinase Inhibitors PRN473 and PRN1008 (Rilzabrutinib)Timothy D Owens, Ken A Brameld, Erik J Verner, et al.
Bioorganic & Medicinal Chemistry Letters|April 26, 2011
3-Amino-pyrazolo[3,4-d]pyrimidines as p38α kinase inhibitors: design and development to a highly selective leadMichael Soth, Sarah Abbot, Allassan Abubakari, et al.
Nature Chemical Biology|May 26, 2015
Prolonged and tunable residence time using reversible covalent kinase inhibitorsJ Michael Bradshaw, Jesse M McFarland, Ville O Paavilainen, et al.
Journal of Medicinal Chemistry|October 17, 2003
Design and synthesis of 4-azaindoles as inhibitors of p38 MAP kinaseAlejandra Trejo, Humberto Arzeno, Michelle Browner, et al.
Journal of Medicinal Chemistry|January 29, 2013
Pyrrolopyrazines as selective spleen tyrosine kinase inhibitorsFernando Padilla, Niala Bhagirath, Shaoqing Chen, et al.
Bioorganic & Medicinal Chemistry Letters|January 29, 2013
Development of amino-pyrimidine inhibitors of c-Jun N-terminal kinase (JNK): kinase profiling guided optimization of a 1,2,3-benzotriazole leadWylie S Palmer, Muzaffar Alam, Humberto B Arzeno, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Journal of Medicinal Chemistry|April 10, 2014
Structure-based drug design of RN486, a potent and selective Bruton's tyrosine kinase (BTK) inhibitor, for the treatment of rheumatoid arthritisYan Lou, Xiaochun Han, Andreas Kuglstatter, et al.
Bioorganic & Medicinal Chemistry Letters|December 28, 2016
Mitigation of reactive metabolite formation for a series of 3-amino-2-pyridone inhibitors of Bruton's tyrosine kinase (BTK)Yan Lou, Francisco Lopez, Yongying Jiang, et al.
Journal of Medicinal Chemistry|February 14, 2014
Using ovality to predict nonmutagenic, orally efficacious pyridazine amides as cell specific spleen tyrosine kinase inhibitorsMatthew C Lucas, Niala Bhagirath, Eric Chiao, et al.
Journal of Medicinal Chemistry|August 11, 2012
Potent and highly selective benzimidazole inhibitors of PI3-kinase deltaJeremy M Murray, Zachary K Sweeney, Bryan K Chan, et al.
Journal of Medicinal Chemistry|March 18, 2022
Discovery of Reversible Covalent Bruton's Tyrosine Kinase Inhibitors PRN473 and PRN1008 (Rilzabrutinib)Timothy D Owens, Ken A Brameld, Erik J Verner, et al.
Bioorganic & Medicinal Chemistry Letters|April 26, 2011
3-Amino-pyrazolo[3,4-d]pyrimidines as p38α kinase inhibitors: design and development to a highly selective leadMichael Soth, Sarah Abbot, Allassan Abubakari, et al.
Nature Chemical Biology|May 26, 2015
Prolonged and tunable residence time using reversible covalent kinase inhibitorsJ Michael Bradshaw, Jesse M McFarland, Ville O Paavilainen, et al.
Journal of Medicinal Chemistry|October 17, 2003
Design and synthesis of 4-azaindoles as inhibitors of p38 MAP kinaseAlejandra Trejo, Humberto Arzeno, Michelle Browner, et al.
Journal of Medicinal Chemistry|January 29, 2013
Pyrrolopyrazines as selective spleen tyrosine kinase inhibitorsFernando Padilla, Niala Bhagirath, Shaoqing Chen, et al.
Bioorganic & Medicinal Chemistry Letters|January 29, 2013
Development of amino-pyrimidine inhibitors of c-Jun N-terminal kinase (JNK): kinase profiling guided optimization of a 1,2,3-benzotriazole leadWylie S Palmer, Muzaffar Alam, Humberto B Arzeno, et al.
Pageof 3